73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Integra LifeSciences Holdings Corp
Closed
SectorHealthcare
13.53 -2.17
Overview
Share price change
24h
Min
13.53
Max
13.74
Income | 479M -5.4M |
|---|---|
Sales | -14M 402M |
Profit margin | -1.344 |
Employees | 4,396 |
EBITDA | 526M 54M |
Recommendations | Sell |
|---|---|
12 Months Forecast | -11.04% downside |
Next Earnings | 24 Feb 2026 |
|---|
Market Cap | -277M 979M |
|---|---|
Previous open | 15.7 |
Previous close | 13.53 |
News Sentiment
By Acuity
40%
60%
150 / 370 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Integra LifeSciences Holdings Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Integra LifeSciences Holdings Corp Forecast
Price Target
By TipRanks
-11.04% downside
12 Months Forecast
Average 12.33 USD -11.04%
High 14 USD
Low 10 USD
Based on 6 Wall Street analysts offering 12 month price targets forIntegra LifeSciences Holdings Corp - Dist in the last 3 months.
Sentiment
By Acuity
150 / 370 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Integra LifeSciences Holdings Corp
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Live chat